160.96 USD
-2.18
1.34%
At close Apr 30, 4:00 PM EDT
After hours
164.07
+3.11
1.93%
1 day
-1.34%
5 days
1.06%
1 month
-3.39%
3 months
-11.41%
6 months
12.65%
Year to date
-4.51%
1 year
19.75%
5 years
-24.75%
10 years
376.78%
 

About: Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.

Employees: 3,600

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

70% more call options, than puts

Call options by funds: $21.3M | Put options by funds: $12.6M

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

27% more capital invested

Capital invested by funds: $6.68B [Q3] → $8.49B (+$1.81B) [Q4]

22% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 50

2.3% more ownership

Funds ownership: 94.31% [Q3] → 96.6% (+2.3%) [Q4]

1% more funds holding

Funds holding: 356 [Q3] → 358 (+2) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 115

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$205
27%
upside
Avg. target
$210
30%
upside
High target
$215
34%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
Jason Bednar
27% 1-year accuracy
10 / 37 met price target
34%upside
$215
Overweight
Maintained
26 Feb 2025
Wells Fargo
Vik Chopra
36% 1-year accuracy
4 / 11 met price target
27%upside
$205
Overweight
Maintained
26 Feb 2025

Financial journalist opinion

Based on 8 articles about MASI published over the past 30 days

Positive
Seeking Alpha
1 day ago
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst.
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Neutral
Business Wire
6 days ago
Masimo to Report First Quarter 2025 Financial Results after Market Close on Tuesday, May 6
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) will release first quarter 2025 financial results for the period ended March 29, 2025, after the market closes on Tuesday, May 6, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer. To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each par.
Masimo to Report First Quarter 2025 Financial Results after Market Close on Tuesday, May 6
Positive
Zacks Investment Research
1 week ago
Why Masimo (MASI) Could Beat Earnings Estimates Again
Masimo (MASI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Masimo (MASI) Could Beat Earnings Estimates Again
Positive
Zacks Investment Research
1 week ago
Why You Shouldn't Bet Against Masimo (MASI) Stock
Masimo (MASI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why You Shouldn't Bet Against Masimo (MASI) Stock
Positive
Zacks Investment Research
3 weeks ago
Here's Why Masimo (MASI) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Masimo (MASI) is a Strong Growth Stock
Neutral
Zacks Investment Research
4 weeks ago
3 Stocks to Buy for "Liberation" From Trump Tariffs & Recession Woes
In 2025, companies like MASI, BSX and HIMS are expected to overcome challenges and sustain strong growth and market leadership.
3 Stocks to Buy for "Liberation" From Trump Tariffs & Recession Woes
Positive
Zacks Investment Research
4 weeks ago
Masimo (MASI) is an Incredible Growth Stock: 3 Reasons Why
Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Masimo (MASI) is an Incredible Growth Stock: 3 Reasons Why
Neutral
Business Wire
4 weeks ago
Masimo to Present in the 24th Annual Needham Virtual Healthcare Conference
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 2:15 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide ar.
Masimo to Present in the 24th Annual Needham Virtual Healthcare Conference
Positive
Zacks Investment Research
1 month ago
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Masimo (MASI) is a Top Growth Stock for the Long-Term
Positive
Zacks Investment Research
1 month ago
3 Reasons Growth Investors Will Love Masimo (MASI)
Masimo (MASI) could produce exceptional returns because of its solid growth attributes.
3 Reasons Growth Investors Will Love Masimo (MASI)
Charts implemented using Lightweight Charts™